Oculis Holding AG (OCS) Gains from Investment Securities (2023 - 2026)
Oculis Holding AG (OCS) posted quarterly Gains from Investment Securities of $10.2 million for Q1 2026, down 23.05% year-over-year from $13.2 million in Q1 2025, and up 150.86% quarter-over-quarter from $4.1 million in Q4 2025.
Analysis
Oculis Holding AG (OCS) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Oculis Holding AG's Gains from Investment Securities history runs 4 years deep, the most recent figure standing at $10.2 million for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 23.05% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $10.7 million (down 61.25% YoY), while the FY2025 annual figure was $14.8 million, down 16.01% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $10.2 million, up from $4.1 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $15.3 million in Q4 2024, with the low at -$3.9 million in Q3 2025.
- The 4-year median for Gains from Investment Securities is $2.8 million (2023), against an average of $3.5 million.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities jumped 1223.05% in 2024, then plunged 854.27% in 2025.
- Oculis Holding AG's Gains from Investment Securities stood at -$1.4 million in 2023, then surged by 1223.05% to $15.3 million in 2024, then tumbled by 73.41% to $4.1 million in 2025, then surged by 150.86% to $10.2 million in 2026.
- Business Quant data shows OCS's Gains from Investment Securities at $10.2 million in Q1 2026, $4.1 million in Q4 2025, and -$3.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.31 Mn |
| Mar 31, 2026 | 10.19 Mn |
| Dec 31, 2025 | 4.06 Mn |
| Sep 30, 2025 | -3.87 Mn |
| Jun 30, 2025 | 282,646.31 |
| Mar 31, 2025 | 13.25 Mn |
| Dec 31, 2024 | 15.28 Mn |
| Sep 30, 2024 | 513,622.22 |
| Jun 30, 2024 | -1.51 Mn |
| Mar 31, 2024 | 3.52 Mn |
| Dec 31, 2023 | -1.36 Mn |
| Sep 30, 2023 | 2.76 Mn |
| Jun 30, 2023 | 2.92 Mn |
| Mar 31, 2023 | -456,250.61 |